Ekf Diagnostics Share Discussion Threads

[tongosti] 18/5/2022 10:00:48

Mr Market's judgement on your broken record nonsense is simply blah blah blah

[tongosti] 18/5/2022 09:13:40

Can't agree more.

[dan_the_epic] 18/5/2022 08:20:22

I disagree. 19x earnings is too expensive in my book when revenues and eps will go sharply backwards this year because of the covid revenue and when there have been a major increase in competition in some of the areas they want to get into because of covid.

And that is assuming they hit their growth numbers when the macro is going to get much worse

[wan] 18/5/2022 08:18:30

Edited/tweaked the above post

[wan] 18/5/2022 08:11:26

Todays AGM Statement reads well, indeed it would appear that some of the investments made in supporting EKF's Growth Strategy look set to start delivering strongly by the end of this year, with potential for "significant revenue growth through to 2024". In my view, that is already starting to read better than the original 'conservative' potential guided in their Growth Strategy presentation.

I remain very interested in the redeployment of Contract Manufacturing and Laboratory Services capacity and skill set into non-COVID related areas, which looks set to start delivering in the current year. I believe there is much more to this aspect than is currently being revealed (for obvious reasons). So, I believe we are likely to get more information as the year unfolds with regard to both contract manufacturing and expansion of EKF's laboratory Services.

There are early signs of growth in the core business compared to 2021, which had broadly recovered to pre-pandemic levels, and is also very encouraging.

[beckaroo] 18/5/2022 08:02:15

Record Q1 last year with Covid revenues included. Matching that this year is a great result.

[dan_the_epic] 18/5/2022 07:58:45

No growth in q1 and macro is about to get worse. Not cheap enough.

[tongosti] 17/5/2022 09:54:57

If this baby doesn't hold the key 30 level, then in all probability the final leg of this long journey South should probably take this to 16. Far less certain this potential last leg is (compared with the previous 48 and 33 milestones) but being under all key moving averages still give this scenario the edge.

[tongosti] 12/5/2022 16:48:01

If only Mr Market would listen to the poor sod. 33 finally captured. Lol

[wan] 12/5/2022 08:26:39

Recall that EKF intends that the new ordinary shares received as a result of its participation in the recent Verici fundraise will be distributed to its own underlying shareholders, along with EKF's existing shareholding in the Company, as soon as reasonably practicable.

With further news flow expected, Verici Dx is one to keep an eye on.

[wan] 12/5/2022 08:07:52

Excellent news from Renalytix spinout and EKF holding, Verici, this morning.

[tongosti] 09/5/2022 12:08:00

Have you mortgaged house and all then?!

[sarcoline] 07/5/2022 17:49:40

Big Oz asset news imminent at CLON as early as Monday 7am. Price target....multibag.

[tongosti] 07/5/2022 17:48:55

If wider markets are in a generational super bubble and SPX and NDX are to go another 50% or more from here, where will certain individual shares trade at? That's right. What most "value" gamblers in this game do not understand (even after losing big) is that if the boat has been sinking with a rising tide, what will happen when the tide goes in reverse?

[p1nkfish] 07/5/2022 15:06:35

Take it private, wait 3 years, re-list.

[p1nkfish] 07/5/2022 15:04:15

>20% of the Nasdaq biotech index supposedly trading for less than cash.

EKF isn't alone (all tarred with the same sort of brush) and with Mills close to maxed out on the % holding who will offer demand for shares to get this moving upwards? No wonder he's in Shares Magazine touting it to ordinary punters.

Have to wait for a catalyst or market sentiment to turn. May take a while.

[tongosti] 06/5/2022 10:41:56

Rivaldo didn't you and your favourite journalists say the same at 80+. What has changed pal?

[rivaldo] 05/5/2022 12:58:11

FYI this is from the new Shares Magazine out today - Christopher Mills talking about North Atlantic's portfolio and EKF in particular:

"For example, shares in portfolio holding EKF Diagnostics (EKF:AIM) have more than halved in value over the past six months. The fact EKF continues to have exposure to Russia has also weighed on its share price.

‘People have forgotten there is a real business in EKF,’ says Mills. ‘We’ll do £16 million of EBITDA (earnings before interest, tax, depreciation and
amortisation) this year and we expect to grow EBITDA – with no revenue from Covid – to £25 million within three years. It’s crazy. Diagnostics businesses don’t trade on six times EBITDA, they trade on 12 to 15-times."

[sirshagalot] 05/5/2022 10:54:25

I ,m in again i believe its worth a small punt

[wan] 05/5/2022 09:10:29

4th May 2022
EKF's team in Cardiff working in the ISO Class 7 Clean Room for a new contract manufacturing services customer -

[tongosti] 04/5/2022 15:51:40

Wise decision my good man. filter button crowd down 60% and counting. Very wise of you chaps ignoring yours truly calling the top at 80+. Even the hard way hasn't taught you anything has it. Knock it out fellas, you're all aces in my book. LOL

[wan] 04/5/2022 15:41:53

James...It's a fair point regarding the filter button preventing clutter and dealing with trolls, albeit I would like to think my responses have been more relevant to EKF (than about T). Anyway, points taken and filter button deployed!

[james188] 04/5/2022 12:10:02

Wan,

It is your call, but a number of others have made the point that the filter button is the best way to deal with trolls (as distinct from people who have a negative view of the share and make valid points which add to the collective knowledge). The last thing that we want is for a decent board to be cluttered up with rubbish.

On the subject of broker notes, I consider them more important in relation to small caps because those companies receive less coverage. So, whilst I would always take share price/revenue forecasts contained in them with a pinch of salt, they do affect investor sentiment and they often contain useful information not otherwise available to investors. Look at the sort of in depth coverage that finncap produces on life sciences companies (TSTL, BVXP etc). That is the sort of objective coverage that I think that EKF should be aiming for.